3 8 3 l e t t e r S Types 1 and 2 diabetes affect some 380 million people worldwide. Both ultimately result from a deficiency of functional pancreatic insulin-producing beta cells. Beta cells proliferate in humans during a brief temporal window beginning around the time of birth, with a peak percentage (~2%) engaged in the cell cycle in the first year of life [1] [2] [3] [4] . In embryonic life and after early childhood, beta cell replication is barely detectable. Whereas beta cell expansion seems an obvious therapeutic approach to beta cell deficiency, adult human beta cells have proven recalcitrant to such efforts 1-8 . Hence, there remains an urgent need for antidiabetic therapeutic agents that can induce regeneration and expansion of adult human beta cells in vivo or ex vivo. Here, using a high-throughput small-molecule screen (HTS), we find that analogs of the small molecule harmine function as a new class of human beta cell mitogenic compounds. We also define dual-specificity tyrosine-regulated kinase-1a (DYRK1A) as the likely target of harmine and the nuclear factors of activated T cells (NFAT) family of transcription factors as likely mediators of human beta cell proliferation and differentiation. Using three different mouse and human islet in vivo-based models, we show that harmine is able to induce beta cell proliferation, increase islet mass and improve glycemic control. These observations suggest that harmine analogs may have unique therapeutic promise for human diabetes therapy. Enhancing the potency and beta cell specificity of these compounds are important future challenges.
l e t t e r S Types 1 and 2 diabetes affect some 380 million people worldwide. Both ultimately result from a deficiency of functional pancreatic insulin-producing beta cells. Beta cells proliferate in humans during a brief temporal window beginning around the time of birth, with a peak percentage (~2%) engaged in the cell cycle in the first year of life [1] [2] [3] [4] . In embryonic life and after early childhood, beta cell replication is barely detectable. Whereas beta cell expansion seems an obvious therapeutic approach to beta cell deficiency, adult human beta cells have proven recalcitrant to such efforts [1] [2] [3] [4] [5] [6] [7] [8] . Hence, there remains an urgent need for antidiabetic therapeutic agents that can induce regeneration and expansion of adult human beta cells in vivo or ex vivo. Here, using a high-throughput small-molecule screen (HTS), we find that analogs of the small molecule harmine function as a new class of human beta cell mitogenic compounds. We also define dual-specificity tyrosine-regulated kinase-1a (DYRK1A) as the likely target of harmine and the nuclear factors of activated T cells (NFAT) family of transcription factors as likely mediators of human beta cell proliferation and differentiation. Using three different mouse and human islet in vivo-based models, we show that harmine is able to induce beta cell proliferation, increase islet mass and improve glycemic control. These observations suggest that harmine analogs may have unique therapeutic promise for human diabetes therapy. Enhancing the potency and beta cell specificity of these compounds are important future challenges.
The growth-mediating MYC proteins are key normal drivers of cell growth for many tissues [9] [10] [11] [12] [13] [14] [15] [16] and lie downstream of numerous physiological, developmental and regenerative mitogenic signaling pathways [9] [10] [11] [12] [13] [14] [15] [16] [17] . More specifically, c-MYC is an essential driver of proliferation in Ins1 and RINm5F rat pancreatic beta cell lines and can drive human beta cell proliferation 17 . Reasoning that the MYC promoter might serve as a useful downstream 'sensor' for multiple diverse upstream signals leading to proliferation, we developed a luciferase-based small-molecule HTS strategy to detect molecules that directly or indirectly activate the MYC promoter in human cells (Fig. 1a, Supplementary Fig. 1 and Online Methods).
We generated multiple stable cell lines expressing a luciferase reporter under control of the human MYC promoter. Among these, the human hepatocyte cell line HepG2 yielded the most robust luciferase responses and the least variability in pilot HTS screens, and we selected it for further screening using two small-molecule libraries: a library from the US Food and Drug Administration consisting of 2,300 small molecules and a 100,000-compound commercial library (see Online Methods). Of the 102,300 compounds tested, 4,500 scored >3 for median absolute deviation (MAD) 18 for luciferase activation (Fig. 1b) . Among these, we assessed the 86 that generated the greatest normalized percentage activation (NPA >7.5%) 19 further for their ability both to induce c-MYC protein expression in HepG2 cells ( Supplementary  Fig. 1 ) and to induce BrdU incorporation in dispersed rat pancreatic beta cells (Fig. 1c) . Only one compound, harmine, induced both a mild increase of c-MYC in HepG2 cells and substantial BrdU incorporation into rat beta cells. Harmine also induced BrdU incorporation and Ki-67 labeling in human beta cells, with the frequent appearance of double nuclei, suggesting recent cell division (Fig. 1d-g ).
Harmine is a competitive inhibitor of ATP binding to the kinase pocket of DYRK1A, but it can also inhibit other DYRK family members, monoamine oxidases (MAOs) and cdc-like kinases (CLKs). We therefore surveyed additional harmine analogs [20] [21] [22] [23] [24] (Fig. 2a) . Harmaline and harmane (inhibitors of MAO but not DYRK1A) did not induce proliferation; conversely, inhibitor of DYRK1A, (INDY, a chemical compound that inhibits DYRK1A but not MAO), activated proliferation in both rat and human beta cells (Fig. 2b-d) , also yielding Ki-67 + and BrdU + double nuclei (Fig. 2d) . Harmine and INDY both also induced phosphorylation of histone H3, a third marker of cell cycle transition (Supplementary Fig. 2) . Effective harmine and A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication l e t t e r S 3 8 4 VOLUME 21 | NUMBER 4 | APRIL 2015 nature medicine ) and "H" harmine. A minimum of 1,000 beta cells was counted from multiple donors (n = 4 for rat, n = 6 for human) for each bar. (g) Quantification of Ki-67 labeling in rat and human beta cells. "C" indicates control (DMSO vehicle) and "H" harmine. A minimum of 1,000 beta cells was counted from multiple donor pairs (4 rat, 7 human) for each bar. In all relevant panels, error bars indicate sem *P < 0.05 and **P < 0.01, as determined by Wilcoxon rank test. Scale bars, 10 µm.
INDY doses were in the 1-to 15-µM range, with higher doses being detrimental to proliferation ( Fig. 2e-h ). WS6, a previously described small-molecule agonist of beta cell proliferation 25 , had little effect on human beta cell proliferation in our hands (Supplementary Fig. 3 ). Ki-67 labeling induced by harmine was unaffected by glucose concentration ( Supplementary Fig. 2c ). Collectively, these observations suggested that DYRK1A or the closely related kinases DYRK1B, DYRK2 or CLKs 1 and 4, are the relevant targets of harmine and INDY. Harmine and INDY also activated proliferation in alpha and ductal cells, with no detectable proliferation in delta cells or pancreatic polypeptide cells (Supplementary Fig. 3 ).
We found no evidence of beta cell death or DNA damage in response to harmine or INDY as measured by TUNEL and p-γ-H2AX labeling (Supplementary Fig. 2 ). We did find that INS mRNA expression in harmine-treated human islets was higher than in vehicletreated islets, but islet insulin content and glucose-stimulated insulin secretion were comparable between harmine-and INDY-treated islets and vehicle-treated controls ( Supplementary  Fig. 4a-c) . Of note, we also found that the transcription factors PDX1, NKX6.1 and MAFA were increased at the mRNA and protein levels and showed potent staining in beta cells by immunocytochemistry ( Supplementary Fig. 4d−j) . To determine whether calcineurin-NFAT signaling [26] [27] [28] might mediate the proliferative effects of harmine analogs in rat and human beta cells (Fig. 3a) , we blocked the NFAT-calcineurin interaction with the NFAT inhibitor VIVIT and inhibited calcineurin activity with FK-506. Both inhibitors attenuated Ki-67 labeling in both rat and human beta cells ( Fig. 3b and Supplementary Fig. 5 ), suggesting a role for calcineurin-NFAT signaling in the effects of harmine and INDY on beta cell proliferation. We therefore surveyed the presence and subcellular localization of NFAT family members in human beta cells. As predicted by prior studies in rodent beta cells [27] [28] [29] and human beta cell RNA sequencing-based studies 30 , NFATs were also detectable in the cytoplasm in quiescent human beta cells ( Supplementary  Fig. 6 ). Both harmine and INDY induced nuclear translocation of all four endogenous NFATs ( Fig. 3c and Supplementary Fig. 6 ). Concordantly, adenovirally expressed NFAT2 (encoded by NFATC1) fused to GFP was readily apparent in the cytoplasm in vehicle-treated beta cells but shifted to a predominantly nuclear location within harmine-and INDY-treated beta cells (Supplementary Fig. 7) .
To further explore whether DYRK1A is a relevant regulator of proliferation in human beta cells, we adenovirally overexpressed DYRK1A in human islets. Notably, though endogenous DYRK1A was detectable in normal quiescent human islets, DYRK1A could effectively be overexpressed, appearing in the nuclear compartment (Fig. 3d,e) ; its overexpression competitively attenuated harmine-and INDYinduced human beta cell proliferation (Fig. 3f) . Conversely, reducing endogenous DYRK1A expression using an adenoviral shRNA directed against human DYRK1A led to a threefold higher degree of proliferation of the human beta cells as compared to a scrambled shRNA-expressing control adenovirus (Fig. 3g-i) .
Harmine and INDY occupy the ATP-binding pocket of DYRK1A, forming two hydrogen bonds with the side chain of Lys188 and the backbone of Leu241, with hydrogen bond acceptor groups in the correct orientation to form these interactions [20] [21] [22] [23] [24] (Supplementary Fig. 7) . Conversely, harmine analogs that lack DYRK1A inhibitory activity and beta cell mitogenic activity (Fig. 2) are expected to fail to bind within the ATP-binding pocket of DYRK1A because they lack one of the hydrogen bond acceptor groups (harmane, norharmane) or because the hydrogen bond acceptor groups are not correctly positioned (harmaline, harmalol) owing to their nonplanar conformation.
As the HTS was based on MYC activation in HepG2 cells, we next asked whether harmine-induced proliferation of human islets required c-MYC activity. Harmine induced a reproducible but moderate (twofold) higher level of c-MYC protein in human islets as compared to vehicle-treated islets, and the c-MYC inhibitor 1RH (ref. 31) inhibited harmine-induced proliferation ( Supplementary  Fig. 8a−d) . Further, adenoviral Cre-mediated excision of Myc from islets of Myc loxP/loxP mice 32 attenuated harmine-induced proliferation ( Supplementary Fig. 8e−h) . Thus, harmine-induced proliferation depends in part on c-MYC activation. Next, to find additional downstream cell cycle mediators of harmine analog action, we performed an mRNA screen of G1/S cell cycle control molecules, which we confirmed by immunoblot and immunocytochemistry. We found higher expression of relevant cyclins and cdks (e.g., cyclins A and E, CDK1, FOXM1, CDC25A, and E2Fs 1 and 2) and lower expression of cell cycle inhibitors (notably, p15 INK4 , p16 INK4 and p57 CIP2 ) in islets treated with harmine or INDY as compared to vehicle-treated islets (Supplementary Fig. 9) .
Finally, we used three different in vivo animal models to assess the ability of harmine to activate proliferation, augment beta cell mass and enhance glycemic control. In the first, a partial pancreatectomy (PPX) model, harmine treatment induced Ki-67 labeling in beta cells in both sham-operated mice and in mice subjected to PPX, with the most robust proliferation in the beta cells of harmine-treated PPX npg l e t t e r S mice (Fig. 4a,b) . In the PPX model, regeneration of beta cell mass was substantially more rapid in the harmine-treated mice than in the controls, reaching near-normal values in only 14 d (Fig. 4c) . In the second model, a euglycemic nonobese diabetic-severe combined immunodeficiency (NOD-SCID) mouse model, BrdU and Ki-67 labeling was two-to threefold higher in human beta cells transplanted into the renal capsule of harmine-treated compared to control euglycemic mice, without evidence of beta cell death (Fig. 4d-h) . In the third model, a marginal mass human islet transplant model in streptozotocin-diabetic NOD-SCID mice, harmine treatment also resulted in near normal glycemic control, as assessed both by postprandial and fasting glucose values and by intraperitoneal glucose tolerance challenge (Fig. 4i,j) .
Harmine and INDY induced human beta cells to enter the cell cycle, both in vitro and in vivo, with beta cell labeling indices that are in the range occurring physiologically in humans during the first year of life, a range that may be relevant to therapeutic beta cell expansion [1] [2] [3] [4] . Harmine not only induced markers of proliferation in rat, mouse and human beta cells in vitro but also increased beta cell mass and regeneration in a mouse PPX model and enhanced glycemic control and beta cell proliferation in vivo in two additional standard human islet transplant models, one euglycemic and one diabetic. Further, and unexpectedly, harmine induced production of the important beta cell transcription factors NKX6.1, PDX1 and MAFA. It appears that harmine analogs may act through the calcium-mediated, calcineurin-driven pathway, activating key cell cycle molecules such as c-MYC, CDK1, cyclins A and E, FOXM1, E2Fs and CDC25A, as well as repressing important cell cycle inhibitors such as p15 INK4 , p16 INK4 and p57 CIP . In parallel, calcineurin-NFAT signaling has also been shown to be essential in mouse genetic models of beta cell growth and differentiation [27] [28] [29] .
We were surprised that DYRK1A inhibition can lead to beta cell expansion. Another group has reported that Dyrk1a haploinsufficiency in mice results in attenuated beta cell mass and glucose intolerance 33, 34 ; conversely, transgenic Dyrk1a overexpression leads to accentuated beta cell size, mass and proliferation, as well as enhanced glucose tolerance 35 . Potential explanations for this paradox may include differences in species, age, timing of expression (developmental phenotypes in mice versus adult treatment), duration of exposure (days in treated human islets versus permanently and constitutively in mouse genetic models), central nervous system targeting (the murine constructs affect all tissues), possible dominant-positive effects of heterozygous loss, and/or differences between drug-induced conformational changes in a given protein versus complete ablation or overexpression of the protein. Furthermore, Dyrk1a is an unusually complex gene, with at least nine different splice variants and up to 17 exons (nomenclature for Dyrk1a exons varies), only one exon of which was eliminated in the gene disruption studies 33, 34 . Unraveling the gene products, cell type-specific isoforms and effects of harmine analogs on these various isoforms will require further study.
Our results support a role for DYRK1A as the relevant target of the harmine analogs and probably exclude closely related kinases such as DYRK1B, DYRK2, DYRK3, DYRK4, and CLKs 1-4. For example, DYRKs 3 and 4 and CLKs 2 and 3 are unlikely targets because harmine analogs are weak inhibitors of these kinases, leaving DYRK1A, DYRK1B, DYRK2, CLK1 and CLK4 as the remaining likely candidates. These cannot easily be distinguished on pharmacologic grounds because the available inhibitors largely overlap. However, the complementary observations that overexpression of DYRK1A blocks, and silencing of DYRK1A mimics, the mitogenic effects of harmine and INDY on human beta cells make DYRK1A the prime candidate for a harmine analog target. Nonetheless, further specificity studies are warranted. As DYRK and CLK family members are widely distributed, existing harmine analogs will probably have off-target effects [20] [21] [22] [23] [24] . For example, harmine is a CNS stimulant 36 , and as noted above, it activates proliferation in alpha and ductal cells in the islet (Supplementary  Fig. 3) . Also, harmine is a peroxisome proliferator and activator of transcription-γ activator and mediator of adipogenesis in mice and leads to enhanced glucose sensitivity and disposal in obese, diabetic db/db mice, although beta cell proliferation, mass and function were not examined in that study 37 . Thus, as is the case for all potential beta cell therapeutics 25, [37] [38] [39] [40] , there is an urgent need to develop strategies to deliver harmine analogs specifically to the beta cell.
In addition, understanding and optimizing the duration and dosing of future potential harmine analogs will be important, as excessive (~50-to 150-fold) Myc expression in mice has adverse consequences, leading to beta cell transformation, death and diabetes [11] [12] [13] [14] [15] [16] [17] . Cell death serves as an evolutionary fail-safe mechanism in all tissues that prevents accidental unrestrained production of c-MYC and tumor growth [9] [10] [11] [12] [13] [14] . The observations that harmine causes only modest, twofold, increases in c-MYC, that the percentage of all beta cells (~1-1.5%) engaged in the cell cycle following harmine treatment is similar to that observed in neonatal life [1] [2] [3] [4] , and that the duration of physiologic proliferation in humans is confined to the first year or few years of life [1] [2] [3] [4] suggest that oncogenic side effects may not occur with harmine analog treatment. The absence of evidence of beta cell death, DNA damage or dedifferentiation in response to harmine analogs is also encouraging.
In summary, harmine analogs are able to induce adult human beta cell cycle entry at rates that are in the physiologic and potentially therapeutic range. Further approaches to optimizing the potency of the harmine analog backbone, of unequivocally defining its molecular targets, and of developing methods to direct it specifically to beta cells are key future challenges.
METHoDS
Methods and any associated references are available in the online version of the paper. 
l e t t e r S oNLINE METHoDS
General experimental approaches. No samples, mice or data points were excluded from the reported analyses. For islet studies, equivalent aliquots of every islet batch were randomly assigned to culture wells or microscope slides. For mouse studies, mice were randomly selected to groups to receive harmine or vehicle control or to receive partial pancreatectomy or sham pancreatectomy. Some analyses were not performed in a blinded fashion. See "Statistical analyses" below for more detail. Cell lines. Four cell lines were initially assessed for the HTS: rat insulinoma cells (Ins1 823/13), mouse insulinoma cells (βTC3), human hepatoma cells (HepG2) and human colon cancer cells (HCT116). The human hepatoma cell line used for these studies, HepG2 (ATCC), was cultured in EMEM medium supplemented with 10% FCS, 1% penicillin-streptomycin. The adenovirus packaging cell line, HEK-293A (Life Technologies), was cultured in DMEM medium supplemented with 10% FCS, and 1% penicillin-streptomycin, and 1× MEM containing non-essential amino acids. Cell lines were not validated by genomic testing and were not tested for mycoplasma.
Generation of stable cell lines. HepG2 cells, βTC3 cells, Ins1 823/13 cells and HCT116 cells were transduced in T25 flasks with plasmid DNA encoding the MYC promoter-driven luciferase reporter construct described below. After transfection for 48 h, the cells were trypsinized and re-seeded using serial dilution into 96-well plates containing 1 µg ml −1 puromycin for selection. After 3 weeks, individual clones were picked and reconsolidated into 24-well plates. Clones were verified as containing the plasmid by luciferase activity.
Small-molecule screening. A 2.5-kb human MYC promoter plasmid was obtained from Addgene 41 . The MYC promoter fragment was excised with SacI and HindIII and ligated into the PGL4.20 luciferase vector (Promega). This was stably introduced into HepG, βTC3, Ins1 823/13 and HCT116 cell lines. HepG2 cell clone 13 ( Supplementary Fig. 1 ) was ultimately selected for the screen because of its stability and robust response (Z′ of 0.75) 18, 19, 42 to the positive controls, IL1-β and TNF-α, in a preliminary screen. These cells were maintained in complete DMEM medium with 1µg ml −1 puromycin. As a positive control, a combination of IL-1β and TNF-α was selected because of the NF-κB sites in the MYC promoter.
Screening was carried out in 384-well format using two commercially sourced libraries. The FDA library (2,300 compounds, Microsource Discovery Systems), composed of compounds approved for use in humans or animals, was used in a pilot screen, and to evaluate the robustness of the assay format. The L1 library (100,000 compounds; Chembridge) is composed of a structurally diverse set of small molecules selected based on their adherence to Lipinski's rule of 5 (ref. 43) , an indication of drug-like properties based on small-molecule structure. All library compounds are stored as 10-mM stocks (DMSO).
For screening, 384-well assay plates (PerkinElmer ProxiPlate 6008230) were pre-filled with HepG2 cells (5,000 cells/well in 10 µl) expressing the luciferase reporter construct. Twenty-four hours after cell addition, compounds from library plates were transferred by pin tool (V&P Scientific) into assay plates at a final concentration of 7.5 µM. As positive control, 1 µl IL-1β was added at a final assay concentration of 5 ng ml −1 (Multidrop Combi; Thermo Scientific). Following 24 h of incubation, luciferase expression was evaluated by the addition of 5 µl luciferase substrate reagent (Neolite PerkinElmer); luminescence was detected after 10 min using an EnVision plate reader (PerkinElmer).
Assay plates were validated using Z-factor (0.5 cutoff) 42 comparing positivecontrol wells to blank wells. Data were normalized against plate controls using normalized percentage activation (NPA) 19 . A subset of 86 positive compounds showing an NPA >15% was selected for secondary screens and IC 50 determination in primary beta cells based on proliferation. Additionally, the entire data set was renormalized using Robust Z-score (a method developed for the analysis of RNAi screens) 18 , and compounds showing a score >3 median absolute deviation (MAD) above the background signal were used for ranked scoring in subsequent structure-activity relationship (SAR) analysis. (Compounds with a Robust Z-score <3 MAD were considered to be negative).
Human, rat and mouse islets. Human islets from 63 donors were obtained through the NIH-supported Integrated Islet Distribution Program (IIDP). The islets were harvested from deceased donors without any identifying information at NIH-approved centers with informed consent and IRB approval at the islet-isolating centers. Donors ranged in age from 18 to 69 years (mean 43.5); 28 were female, 35 were male. There was no relationship between age and the ability of harmine to activate proliferation within these age constraints. Mean BMI was 29.4 (range , and cold ischemia time was 635 min (range 121-1,150). Purity ranged from 50% to 95%. Rat islets were isolated from 8-to 10-week-old male Wistar rats (Charles River Laboratories, Wilmington, MA) as described previously 44, 45 . Mouse islets were isolated from 8-to 10-week-old male and female Myc loxP/loxP mice 32 . Isolated rat and mouse islets were cultured in RPMI 1640 medium (Life Technologies) containing 10% FCS, 5.5 mM glucose, and 1% penicillin-streptomycin for 24 h. Islets were dispersed by trypsinization. All animal studies were performed in compliance with, and with approval of, the Icahn School of Medicine at Mount Sinai Institutional Animal Care and Use Committee.
Islet dispersion. Islets were dispersed as described [46] [47] [48] [49] , centrifuged at 1,500 r.p.m. for 10 min, washed twice in PBS, resuspended in 1 ml of 1 mg ml −1 trypsin, and incubated for 10 min at 37 °C. During this digestion, the islets were dispersed by gentle pipetting up and down every 5 min for 10 s. Complete RPMI medium containing 5.5 mM glucose, 1% penicillin/streptomycin with 10% FBS was then added to stop the digestion. The cells were then centrifuged for 5 min at 1,500 r.p.m., the supernatants removed, the pellet resuspended in complete medium, and cells then plated on coverslips with 50 µl cell suspension per coverslip. For rat islets, poly-d-lysine/laminin-treated cover slides were used. Cells were then allowed to attach for 2 h at 37 °C or were transduced with adenovirus for 2 h. For Myc loxP/loxP mouse islet studies, islets were isolated and dispersed on poly-d-lysine/laminin-treated cover slips and transduced with Ad.Lacz or Ad.Cre. After 2 h, 500 µl complete RPMI medium was added in each well to terminate the adenoviral transduction. Cells were cultured for 48-96 h as described in the figure legends.
Compound treatments. For compound treatment, after dispersed islets were allowed to recover from dispersal on coverslip 24 h, complete medium was replaced with the medium containing compounds for 3-96 h. Specifically, for Ki-67 staining and BrdU staining, the cells were treated with compounds for 72 h, and BrdU labeling was for 72 h. For phospho-histone-3 staining, the cells were treated with compounds for 96 h. For Ad.NFATC1-GFP nuclear translocation, the cells were transduced with adenovirus for 48 h, after which cells were treated with harmine or INDY for 3 h. For inhibitor experiments with VIVIT or FK506, cells were pretreated with inhibitor for 2 h before addition of harmine or INDY.
Immunocytochemistry. Islet cells on coverslips were fixed in fresh 4% paraformaldehyde for 15 min at 25 °C, washed with PBS and incubated in blocking buffer (1.0% BSA, 0.5% Triton, and 5% normal goat serum (NGS) in PBS) for 1 h at 25 °C. Cells on coverslips were incubated with primary antisera overnight at 4 °C in blocking buffer. Secondary antisera were added for 1 h at 25 °C in secondary buffer (1% BSA, 0.5% Triton in PBS, 5% NGS). For phosphohistone-3 and phospho-γ-H2AX, primary antibody was exposed 2 h at 25 °C. TUNEL labeling was performed according to Promega instructions (G3250, Promega). BrdU immunocytochemistry was performed using 1N HCL antigen-retrieval for 30 min at 37 °C after fixation. Primary antisera were as follows: BrdU (ab6326, Abcam, 1:300), Ki-67 (RM-9106-s1, Thermo Scientific, 1:300), p-Histone-3 (06-570, Millipore, 1:500), insulin (A0564, DAKO, 1:500), NFAT1 (ab2722, Abcam, 1:100), NFAT2 (556602, BD Pharmingen, 1:100), NFAT3 npg
